AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|AAPL339.50-3.44 (-1.00%) ▼|ABBV289.08+6.40 (+2.26%) ▲|ABT102.45-1.61 (-1.55%) ▼|ACN239.12+2.19 (+0.92%) ▲|ADBE256.73+9.64 (+3.90%) ▲|AMAT404.98-8.13 (-1.97%) ▼|AMD534.74-3.31 (-0.62%) ▼|AMGN438.94+14.00 (+3.29%) ▲|AMT183.56+0.53 (+0.29%) ▲|AMZN262.63+0.18 (+0.07%) ▲|AVGO334.37-0.22 (-0.07%) ▼|AXP318.34+1.93 (+0.61%) ▲|BA190.47-0.95 (-0.50%) ▼|BAC50.64+0.25 (+0.50%) ▲|BKNG163.92+1.32 (+0.81%) ▲|BLK1,128.68+4.08 (+0.36%) ▲|BMY61.68+2.85 (+4.84%) ▲|BNY144.25+1.81 (+1.27%) ▲|BRK-B539.82+7.59 (+1.43%) ▲|C122.51+0.82 (+0.67%) ▲|CAT725.24-0.55 (-0.08%) ▼|CL94.54+1.68 (+1.81%) ▲|CMCSA22.36+0.46 (+2.10%) ▲|COF201.56+1.73 (+0.87%) ▲|COP145.95+0.71 (+0.49%) ▲|COST994.61-0.92 (-0.09%) ▼|CRM242.43-0.02 (-0.01%) ▼|CSCO106.71+0.21 (+0.20%) ▲|CVS94.75+2.07 (+2.23%) ▲|CVX225.71+1.34 (+0.60%) ▲|DE632.20+5.20 (+0.83%) ▲|DHR224.24-0.19 (-0.08%) ▼|DIS111.67+2.08 (+1.90%) ▲|DUK121.33+2.06 (+1.73%) ▲|EMR160.46-0.08 (-0.05%) ▼|FDX298.76+4.98 (+1.70%) ▲|GD344.44+3.01 (+0.88%) ▲|GE299.87-11.41 (-3.67%) ▼|GEV890.33-18.11 (-1.99%) ▼|GILD156.51+3.44 (+2.25%) ▲|GM77.09-5.66 (-6.84%) ▼|GOOG336.40-3.76 (-1.11%) ▼|GOOGL340.28-3.91 (-1.13%) ▼|GS884.81+9.03 (+1.03%) ▲|HD315.11+5.23 (+1.69%) ▲|HON213.32+3.34 (+1.59%) ▲|IBM241.92+5.53 (+2.34%) ▲|INTC91.69-0.34 (-0.37%) ▼|INTU335.29+9.67 (+2.97%) ▲|ISRG438.00+4.82 (+1.11%) ▲|JNJ259.36+5.57 (+2.19%) ▲|JPM335.26+1.73 (+0.52%) ▲|KO93.49+0.07 (+0.07%) ▲|LIN501.89-1.55 (-0.31%) ▼|LLY1,283.66+43.32 (+3.49%) ▲|LMT548.71+0.48 (+0.09%) ▲|LOW198.53+2.61 (+1.33%) ▲|LRCX263.45-8.75 (-3.21%) ▼|MA620.42+4.02 (+0.65%) ▲|MCD246.52+3.85 (+1.59%) ▲|MDLZ63.99+0.65 (+1.03%) ▲|MDT94.63+1.86 (+2.01%) ▲|META694.25-11.19 (-1.59%) ▼|MMM171.37+9.36 (+5.78%) ▲|MO74.64+0.55 (+0.74%) ▲|MRK148.30+4.67 (+3.25%) ▲|MS180.40+1.93 (+1.08%) ▲|MSFT531.87-1.65 (-0.31%) ▼|MU896.07-8.83 (-0.98%) ▼|NEE78.86+0.69 (+0.88%) ▲|NFLX68.69-1.16 (-1.66%) ▼|NKE37.88+0.67 (+1.80%) ▲|NOW149.54+4.18 (+2.88%) ▲|NVDA216.47-0.62 (-0.29%) ▼|ORCL131.14+1.55 (+1.20%) ▲|PEP134.02+0.45 (+0.34%) ▲|PFE30.11+0.67 (+2.28%) ▲|PG159.32+1.63 (+1.03%) ▲|PLTR192.60-1.55 (-0.80%) ▼|PM199.90-1.15 (-0.57%) ▼|QCOM175.71+2.18 (+1.26%) ▲|RTX193.34+1.23 (+0.64%) ▲|SBUX99.37+1.50 (+1.53%) ▲|SCHW90.89+1.31 (+1.46%) ▲|SO90.71+1.44 (+1.61%) ▲|SPG206.99+4.50 (+2.22%) ▲|T23.42+0.22 (+0.95%) ▲|TMO687.37+7.99 (+1.18%) ▲|TMUS157.75+1.66 (+1.06%) ▲|TSLA373.71+5.65 (+1.54%) ▲|TXN277.78+1.63 (+0.59%) ▲|UBER68.94-1.02 (-1.46%) ▼|UNH419.26+12.38 (+3.04%) ▲|UNP287.61+0.60 (+0.21%) ▲|UPS98.52+1.06 (+1.09%) ▲|USB59.09+1.24 (+2.14%) ▲|V406.57+3.65 (+0.91%) ▲|VZ44.54+0.39 (+0.88%) ▲|WFC82.20+0.40 (+0.49%) ▲|WMT117.85-0.85 (-0.72%) ▼|XOM177.86-0.42 (-0.24%) ▼|
10.8 C
New York
Wednesday, October 21, 2026

Tag: practice

ROSEN, A LONGSTANDING LAW FIRM, Encourages Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund Investors to Secure Counsel...

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of shares of the Easterly ROCMuni High Income Municipal Bond Fund f/k/a Principal Street High Income Municipal Fund (the “Fund”) (tickers: RMJAX, RMHVX, RMHIX), between May 5, 2023 and June 12, 2025, inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline. The Fund is a mutual fund within defendant James Alpha Funds Trust’s series of mutual funds (which does business as Easterly Funds Trust).

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm...

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.

Ty J. Young Wealth Management Launches “The Official Guide to Selling Your Annuity Business” to Support Growing Acquisition Strategy

ATLANTA, Aug. 4, 2025 /PRNewswire/ -- Ty J. Young Wealth Management, a leading wealth management firm, today announced the release of its new ebook,...

Velocity Trader Exposes Wall Street’s Hidden Friday Price Strategy Used to Trigger Short-Term Market Wins

Jim Fink Investing’s Velocity Trader system reveals how weekly options expiration patterns may create consistent, short-term price setups for traders seeking three- to ten-day market opportunities.
Jim Fink Investing’s Velocity Trader system reveals how weekly options expiration patterns may create consistent, short-term price setups for traders seeking three- to ten-day market opportunities.

DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public.

LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM CONSEQUENCES OF DANGEROUS ‘BURN LINES’ SOCIAL MEDIA TREND

PARIS, Aug. 5, 2025 /PRNewswire/ -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young...

Hims & Hers Health, Inc. (HIMS) – Lawmakers Urge Crackdown On Illegal Weight Loss Drugs, Novo’s Termination of Collaboration With HIMS Triggers Securities Class...

HIMS Investors with Losses Encouraged to Contact Hagens Berman
HIMS Investors with Losses Encouraged to Contact Hagens Berman

Media advisory: Shriners Hospitals for Children Canada Invites Media to its Annual Golf Tournament

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) --

About Shriners Hospitals for Children Canada
Established in Montreal in 1925, Shriners Hospitals for Children Canada is a bilingual, short-term, acute care hospital, providing ultra-specialized orthopaedic care to children from across Canada and around the world. The mission of the hospital is to provide treatment and rehabilitation to infants, children and young adults with orthopaedic and neuromuscular problems such as scoliosis, osteogenesis imperfecta (brittle bone disease), clubfeet, hip dysplasia, leg length discrepancies and cerebral palsy, among others. The hospital is committed to excellence and innovation in clinical practice, research and education. Affiliated with McGill University, the hospital provides clinical experience and teaching for residents and allied professionals within its outstanding new facility on the Glen site. The hospital is present in communities across Canada, thanks to telemedicine, outreach clinics and satellite clinics.

L’Avenue Derm: The Blueprint for Seven-Day Dermatologic Care, Revolutionizing Skin Health and Aesthetics

L’Avenue Derm debuts in Manhattan with a one-month waitlist, redefining holistic dermatologic care. Members receive 7-day access to top dermatologists, yoga, nutrition, and tailored aesthetic treatments—seamlessly blending convenience and clinical excellence at every touchpoint.

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Replimune Group (REPL) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to...

ATLANTA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times.

CloudMasonry Announces Salesforce Marketing Cloud Next Focused Team

Leading Salesforce consulting partner CloudMasonry announced today that it has launched a dedicated Marketing Cloud Next consulting team to help organizations harness Salesforce's new...

Harvard Professor Joseph Fuller joins Hakluyt’s board of directors

LONDON, Aug. 4, 2025 /PRNewswire/ -- Hakluyt, the global strategic advisory firm for businesses and investors, is delighted to announce the appointment of Professor...

MDLifespan and Dr. Jill Carnahan Launch “Next Gen Mold Detox” Using Therapeutic Plasma Exchange

Dr Jill's MDLifespan Mold Protocol is the First Clinically Proven Therapeutic Plasma Exchange Detox to Remove up to 90% of Mold Toxins DENVER, Aug. 4,...

TreeHouse Foods Announces 2025 Sustainability Report

OAK BROOK, Ill., Aug. 4, 2025 /PRNewswire/ -- TreeHouse Foods, Inc. (NYSE: THS) today released its 2025 Sustainability Report, which captures progress made during...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPractice